Drugs / TQB2440
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05985187 | Oct 2020 → Jan 2023 | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05985187 ↗ |
| Route | Intravenous | “TQB2440 injection + Trastuzumab + Docetaxel, intravenous infusion on the first day of each cycle” NCT05985187 ↗ |